Chemotherapy-induced polyneuropathy. Part I. Pathophysiology

Wspolczesna Onkologia

Volumn 16, Issue 1, 2012, Pages 72-78

  Brzeziński, Krzysztof ^a  

^a INSTITUTE OF AGRICULTURAL MEDICINE   (Poland)

Author keywords

Chemotherapy induced polyneuropathy; Neuropathic pain; Pathophysiology; Side effects

Indexed keywords

5 ETHYNYLURACIL; ARSENIC TRIOXIDE; BORTEZOMIB; CAPECITABINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; FLUDARABINE; FLUOROURACIL; GEMCITABINE; LENALIDOMIDE; LEVAMISOLE; METHOTREXATE; OXALIPLATIN; PODOPHYLLOTOXIN DERIVATIVE; PROCARBAZINE; SURAMIN; TIPIFARNIB; VINCA ALKALOID;

ARTHRALGIA; ATAXIA; BRAIN DISEASE; CHEMOTHERAPY INDUCED POLYNEUROPATHY; DRUG FEVER; FATIGUE; FOOT DROP; HAND FOOT SYNDROME; HUMAN; LIVER TOXICITY; MULTIPLE MYELOMA; MYALGIA; NEUROPATHY; NEUROTOXICITY; ORAL PARESTHESIA; PARESTHESIA; PATHOPHYSIOLOGY; PERIPHERAL NERVOUS SYSTEM; PERIPHERAL NEUROPATHY; POLYNEUROPATHY; REVIEW; SKIN REDNESS; SOMNOLENCE; SPINAL CORD DISEASE; SWELLING;

EID: 84857972304     PISSN: 14282526     EISSN: None     Source Type: Journal    
DOI: 10.5114/wo.2012.27341     Document Type: Review

References (107)

1. Ziółkowska E, Zarzycka M, Meller A, Wiśniewski T. Powikłania oczne po radioterapii nowotworów regionu głowy i szyi - przegla̧d piśmiennictwa. Wspolczesna Onkol 2009; 13: 251-4.
2. Dougherty PM, Cata JP, Cordella JV, Burton A, Weng HR, et al. Taxolinduced sensory disturbance is characterized by preferential impairment of myelinated fiber function in cancer patients. Pain 2004; 109: 132-42. (Pubitemid 38479779)
3. Flatters SJ, Bennett GJ. Ethosuximide reverses paclitaxel- and vincristineinduced painful peripheral neuropathy. Pain 2004; 109: 150-61. (Pubitemid 38479781)
4. Flatters SJ, Bennett GJ. Studies of peripheral sensory nerves in paclitaxel- induced painful peripheral neuropathy: evidence for mitochondrial dysfunction. Pain 2006; 122: 245-57. (Pubitemid 43729476)
5. Bennett GJ. Pathophysiology and animal models of cancer-related painful peripheral neuropathy. Oncologist 2010; 15: 9-12.
6. Kaley TJ, Deangelis LM. Therapy of chemotherapy-induced peripheral neuropathy. Br J Haematol 2009; 145: 3-14.
7. Windebank AJ, Grisold W. Chemotherapy-induced neuropathy. J Peripheral Nerv Syst 2008; 13: 27-46. (Pubitemid 351393018)
8. Ramirez JJ, Kaufmann SH, Windebank AJ. Paclitaxel potentiates cisplatin neurotoxicity in dorsal root ganglion neurons. Neurology 1996; 46: A288.
9. Sun X, Windebank AJ. Hypoxia potentiates suramin neurotoxicity in rat dorsal root ganglia in vitro. Soc Neurosci 1996; Abstr 22: 948.
10. Pachman DR, Barton DL, Watson JC, Loprinzi CL. Chemotherapyinduced peripheral neuropathy: prevention and treatment. Clin Pharmacol Ther 2011; 3: 377-87.
11. Wolf S, Barton D, Kottschade L, Grothey A, Loprinzi C. Chemotherapy- induced peripheral neuropathy: prevention and treatment strategies. Eur J Cancer 2008; 44: 1507-15.
12. Verstappen CC, Koeppen S, Heimans JJ, Huijgens PC, Scheulen ME, Strumberg D, Kiburg B, Postma TJ. Dose-related vincristine-induced peripheral neuropathy with unexpected off-therapy worsening. Neurology 2005; 64: 1076-1077. (Pubitemid 40388469)
13. Casanova-Molla J, Grau-Junyent JM, Morales M, Valls-Solé J. On the relationship between nociceptive evoked potentials and intraepidermal nerve fiber density in painful sensory polyneuropathies. Pain 2011; 152: 410-8.
14. Gajos A, Kieliś W, Szadkowska I, Chmielowska E, Niewodniczy A, Bogucki A. Opis przypadku. Nabyte neuropatie obwodowe wprzebiegu gammapatii monoklonalnych. Neurologia i Neurochirurgia Polska 2007; 41: 169-75. (Pubitemid 46745854)
15. Chauvenet AR, Shashi V, Selsky C, Morgan E, Kurtzberg J, Bell B. Vincristine- induced neuropathy as the initial presentation of charcotmarie- tooth disease in acute lymphoblastic leukemia: a Pediatric Oncology Group study. J Pediatr Hematol Oncol 2003; 25: 316-20. (Pubitemid 36506220)
16. Graf WD, Chance PF, Lensch MW, Eng LJ, Lipe HP, Bird TD. Severe vincristine neuropathy in Charcot-Marie-Tooth disease type 1A. Cancer 1996; 77: 1356-62. (Pubitemid 26102336)
17. Bakshi N, Maselli RA, Gospe SM Jr, Ellis WG, McDonald C, Mandler RN. Fulminant demyelinating neuropathy mimicking cerebral death. Muscle Nerve 1997; 20: 1595-7. (Pubitemid 27512351)
18. Orejana-García AM, Pascual-Huerta J, Pérez-Melero A. Charcot- Marie-Tooth disease and vincristine. J Am Podiatr Med Assoc 2003; 93: 229-33.
19. Goetz MP, Erlichman C, Windebank AJ, et al. Phase I and pharmacokinetic study of two different schedules of oxaliplatin, irinotecan, Fluorouracil, and leucovorin in patients with solid tumors. J Clin Oncol 2003; 21: 3761-9. (Pubitemid 46606230)
20. Gregg RW, Molepo JM, Monpetit VJ, Mikael NZ, Redmond D, Gadia M, Stewart DJ. Cisplatin neurotoxicity: the relationship between dosage, time, and platinum concentration in neurologic tissues, and morphologic evidence of toxicity. J Clin Oncol 1992; 10: 795-803.
21. Screnci D, McKeage MJ, Galettis P, Hambley TW, Palmer BD, Baguley BC. Relationships between hydrophobicity, reactivity, accumulation and peripheral nerve toxicity of a series of platinum drugs. Br J Cancer 2000; 82: 966-72. (Pubitemid 30085253)
22. Thompson SW, Davis LE, Kornfeld M, Hilgers RD, Standefer JC. Cisplatin neuropathy. Clinical, electrophysiologic, morphologic, and toxicologic studies. Cancer 1984; 54: 1269-75. (Pubitemid 14003522)
23. Anzil AP, Blinzinger K, Herrlinger H. Fenestrated blood capillaries in rat cranio-spinal sensory ganglia. Cell Tissue Res 1976; 167: 563-7.
24. Jacobs JM. Vascular permeability and neurotoxicity. Environ Health Perspect 1978; 26: 107-16. (Pubitemid 9076100)
25. Olsson Y. Studies on vascular permeability in peripheral nerves. IV. Distribution of intravenously injected protein tracers in the peripheral nervous system of various species. Acta Neuropathol 1971; 17: 114-26.
26. McDonald ES, Randon KR, Knight A, Windebank AJ. Cisplatin preferentially binds to DNA in dorsal root ganglion neurons in vitro and in vivo: a potential mechanism for neurotoxicity. Neurobiol Dis 2005; 18: 305-13. (Pubitemid 40431114)
27. Ta LE, Espeset L, Podratz J, Windebank AJ. Neurotoxicity of oxaliplatin and cisplatin for dorsal root ganglion neurons correlates with platinum-DNA binding. Neurotoxicology 2006; 27: 992-1002. (Pubitemid 44838955)
28. Gill JS, Windebank AJ. Cisplatin-induced apoptosis in rat dorsal root ganglion neurons is associated with attempted entry into the cell cycle. J Clin Invest 1998; 101: 2842-50. (Pubitemid 28294593)
29. Podratz JL, Schlattau AW, Chen BK, Knight AM, Windebank AJ. Platinum adduct formation in mitochondrial DNA may underlie the phenomenon of coasting. J Peripher Nerv Syst 2007; 12: 69.
30. Eeles R, Tait DM, Peckham MJ. Lhermitte's sign as a complication of cisplatin-containing chemotherapy for testicular cancer. Cancer Treat Rep 1986; 70: 905-7. (Pubitemid 16058559)
31. Krarup-Hansen A, Fugleholm K, Helweg-Larsen S, Hauge EN, Schmalbruch H, Trojaborg W, Krarup C. Examination of distal involvement in cisplatin-induced neuropathy in man. An electrophysiological and histological study with particular reference to touch receptor function. Brain 1993; 116: 1017-41. (Pubitemid 23329879)
32. Fu KK, Kai EF, Leung CK. Cisplatin neuropathy: a prospective clinical and electrophysiological study in Chinese patients with ovarian carcinoma. J Clin Pharm Ther 1995; 20: 167-72.
33. McKeage MJ. Comparative adverse effect profiles of platinum drugs. Drug Saf 1995; 13: 228-44.
34. Ozols RF, Ostchega Y, Myers CE, Young RC. High-dose cisplatin in hypertonic saline in refractory ovarian cancer. J Clin Oncol 1985; 3: 246-50.
35. Walsh TJ, Clark AW, Parhad IM, Green WR. Neurotoxic effects of cisplatin therapy. Arch Neurol 1982; 39: 719-20. (Pubitemid 12003431)
36. Mollman JE, Hogan WM, Glover DJ, McCluskey LF. Unusual presentation of cis-platinum neuropathy. Neurology 1988; 38: 488-90. (Pubitemid 18083696)
37. Grunberg SM, Sonka S, Stevenson LL, Muggia FM. Progressive paresthesias after cessation of therapy with very high-dose cisplatin. Cancer Chemother Pharmacol 1989; 25: 62-4. (Pubitemid 20000800)
38. Hansen RA, Gartlehner G, Powell GE, Sandler RS. Serious adverse events with infliximab: analysis of spontaneously reported adverse events. Clin Gastroenterol Hepatol 2007; 5: 729-35.
39. Gamelin E, Gamelin L, Bossi L, Quasthoff S. Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures. Semin Oncol 2002; 29: 21-33. (Pubitemid 35191038)
40. Raymond E, Chaney SG, Taamma A, Cvitkovic E. Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol 1998; 9: 1053-71. (Pubitemid 28518143)
41. Grothey A.Oxaliplatin-safety profile: neurotoxicity. Semin Oncol 2003; 30: 5-13. (Pubitemid 37259547)
42. Lehky TJ, Leonard GD, Wilson RH, Grem JL, Floeter MK. Oxaliplatininduced neurotoxicity: acute hyperexcitability and chronic neuropathy. Muscle Nerve 2004; 29: 387-92. (Pubitemid 38269758)
43. Kiernan MC, Krishnan AV. The pathophysiology of oxaliplatin-induced neurotoxicity. Curr Med Chem 2006; 13: 2901-7. (Pubitemid 44509715)
44. Leonard GD, Wagner MR, Quinn MG, Grem JL. Severe disabling sensory- motor polyneuropathy during oxaliplatinbased chemotherapy. Anticancer Drugs 2004; 15: 733-5. (Pubitemid 39099924)
45. International Collaborative Ovarian NeoPlasm Group. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet 2002; 360: 505-15.
46. Voltz RD, Posner JB, Dalmau J, Graus F. Paraneoplastic encephalomyelitis: an update of the effects of the anti-Hu immune response on the nervous system and tumour. J Neurol Neurosurg Psychiatry 1997; 63: 133-6. (Pubitemid 27388957)
47. Graus F, Keime-Guibert F, Reñé R, Benyahia B, Ribalta T, Ascaso C, Escaramis G, Delattre JY. Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain 2001; 124: 1138-48. (Pubitemid 32510382)
48. Bryl M, Ramlau R, Dyszkiewicz W. Postȩpowanie w zaawansowanych inwazyjnych grasiczakach - przegla̧d piśmiennictwa. Wspolczesna Onkol 2004; 8: 148-52.
49. Albers J, Chaudhry V, Cavaletti G, Donehower R. Interventions for preventing neuropathy caused by cisplatin and related compounds. Cochrane Database Syst Rev 2007; CD005228.
50. Paulson JC, McClure WO. Inhibition of axoplasmic transport by colchicine, podophyllotoxin, and vinblastine: an effect on microtubules. Ann N Y Acad Sci 1975; 253: 517-27.
51. Jackson DV Jr, Castle MC, Poplack DG, Bender RA. Pharmacokinetics of vincristine in the cerebrospinal fluid of subhuman primates. Cancer Res 1980; 40: 722-4. (Pubitemid 10174895)
52. Greig NH, Soncrant TT, Shetty HU, Momma S, Smith QR, Rapoport SI. Brain uptake and anticancer activities of vincristine and vinblastine are restricted by their low cerebrovascular permeability and binding to plasma constituents in rat. Cancer Chemother Pharmacol 1990; 26: 263-8. (Pubitemid 20211111)
53. Schaumburg H. Vinca Alkaloids. In: Experimental and Clinical Neurotoxicology. 2nd ed. Schaumburg H, Spencer P (eds.). Oxford University Press, New York 2000; 1232-5.
54. Pan YA, Misgeld T, Lichtman JW, Sanes JR. Effects of neurotoxic and neuroprotective agents on peripheral nerve regeneration assayed by time-lapse imaging in vivo. J Neurosci 2003; 23: 11479-88. (Pubitemid 37549705)
55. Sahenk Z, Brady ST, Mendell JR. Studies on the pathogenesis of vincristine- induced neuropathy. Muscle Nerve 1987; 10: 80-4. (Pubitemid 17223315)
56. Iqbal Z, Ochs S. Uptake of Vinca alkaloids into mammalian nerve and its subcellular components. J Neurochem 1980; 34: 59-68. (Pubitemid 10172678)
57. Fazeny B, Zifko U, Meryn S, Huber H, Grisold W, Dittrich C. Vinorelbine- induced neurotoxicity in patients with advanced breast cancer pretreated with paclitaxel - a phase II study. Cancer Chemother Pharmacol 1996; 39: 150-6. (Pubitemid 26400674)
58. Burns BV, Shotton JC. Vocal fold palsy following vinca alkaloid treatment. J Laryngol Otol 1998; 112: 485-7. (Pubitemid 28271849)
59. Sanderson PA, Kuwabara T, Cogan DG. Optic neuropathy presumably caused by vincristine therapy. Am J Ophthalmol 1976; 81: 146-50.
60. Lugassy G, Shapira A. Sensorineural hearing loss associated with vincristine treatment. Blut 1990; 61: 320-1.
61. Kalcioglu MT, Kuku I, Kaya E, Oncel S, Aydogdu I. Bilateral hearing loss during vincristine therapy: a case report. J Chemother 2003; 15: 290-2. (Pubitemid 36819319)
62. Low PA, Vernino S, Suarez G. Autonomic dysfunction in peripheral nerve disease. Muscle Nerve 2003; 27: 646-61. (Pubitemid 36667473)
63. Hohneker JA. A summary of vinorelbine (Navelbine) safety data from North American clinical trials. Semin Oncol 1994; 21: 42-7. (Pubitemid 24347164)
64. Curran MP, Plosker GL. Vinorelbine: a review of its use in elderly patients with advanced non-small cell lung cancer. Drugs Aging 2002; 19: 695-721. (Pubitemid 35252500)
65. Moudgil SS, Riggs JE. Fulminant peripheral neuropathy with severe quadriparesis associated with vincristine therapy. Ann Pharmacother 2000; 34: 1136-8.
66. Glantz MJ, Cole BF, Glantz LK, Cobb J, Mills P, Lekos A, Walters BC, Recht LD. Cerebrospinal fluid cytology in patients with cancer: minimizing false-negative results. Cancer 1998; 82: 733-9. (Pubitemid 28090286)
67. Dworkin RH, O'Connor AB, Backonja M, et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain 2007; 132: 237-51. (Pubitemid 350051570)
68. Finnerup NB, Sindrup SH, Jensen TS. The evidence for pharmacological treatment of neuropathic pain. Pain 2010; 150: 573-81.
69. Dworkin RH, O'Connor AB, Audette J, et al. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc 2010; 85 (3 Suppl): S3-14.
70. Dzierżanowski T, Ciałkowska-Rysz A. Neuropathic pain in palliative care patients. Medycyna Paliatywna 2010; 2: 57-66.
71. Apfel S. Taxoids. In: Experimental and Clinical Neurotoxicology. 2nd ed. Schaumburg H, Spencer P (eds.). Oxford University Press, New York 2000; 1135-9.
72. Postma TJ, Vermorken JB, Liefting AJ, Pinedo HM, Heimans JJ. Paclitaxel-induced neuropathy. Ann Oncol 1995; 6: 489-94.
73. Hilkens PH, Verweij J, Vecht CJ, Stoter G, van den Bent MJ. Clinical characteristics of severe peripheral neuropaty induced by docetaxel (Taxotere). Ann Oncol 1997; 8: 187-90. (Pubitemid 27112888)
74. Boillot A, Cordier A, Guerault E, Julliot MC, Balvay P, Billerey C, Barale F (1989): A rare case of severe toxic peripheral neuropathy: poisoning by podophyllin. Apropos of 1 case. J Toxicol Clin Exp 1989; 9: 409-12. (Pubitemid 20162936)
75. Rogalska A, Marczak A, Szwed M, Gajek A, Jóźwiak Z. Epotilony -nadzieja dla pacjentów niewrażliwych na leczenie taksanami. Wspolczesna Onkol 2010; 14: 205-10.
76. Brat DJ, Windebank AJ, Brimijoin S. Emulsifier for intravenous cyclosporin inhibits neurite outgrowth, causes deficits in rapid axonal transport and leads to structural abnormalities in differentiating N1E.115 neuroblastoma. J Pharmacol Exp Ther 1992; 261: 803-10.
77. Bilińska M, Usnarska-Zubkiewicz L, Dmoszyńska A. Polineuropatia wywołana talidomidem i bortezomibem u chorych na szpiczaka mnogiego, możliwości leczenia bólu neuropatycznego. Zalecenia Polskiej Grupy Szpiczakowej. Wspolczesna Onkol 2008; 12: 441-6.
78. Patel SR, Vadhan-Raj S, Papadopolous N, Plager C, Burgess MA, Hays C, Benjamin RS. High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies - dose-response and schedule dependence. J Clin Oncol 1997; 15: 2378-84. (Pubitemid 27251141)
79. Spivack SD. Drugs 5 years later: procarbazine. Ann Intern Med 1974; 81: 795-800.
80. Gutin PH, Levi JA, Wiernik PH, Walker MD. Treatment of malignant meningeal disease with intrathecal thioTEPA: a phase II study. Cancer Treat Rep 1977; 61: 885-7. (Pubitemid 8167617)
81. Martín Algarra S, Henriquez I, Rebollo J, Artieda J. Severe polyneuropathy and motor loss after intrathecal thiotepa combination chemotherapy: description of two cases. Anticancer Drugs 1990; 1: 33-5.
82. Cairncross G, Swinnen L, Bayer R, et al. Myeloablative chemotherapy for recurrent aggressive oligodendroglioma. Neuro Oncol 2000; 2: 114-9.
83. Cho ES. Toxic effects of adriamycin on the ganglia of the peripherial nervous system: a neuropathological study. J Neuropathol Exp Neurol 1977; 36: 907-15. (Pubitemid 8238367)
84. Bigotte L, Olsson Y. Retrograde transport of doxorubicin (adriamycin) in peripheral nerves of mice. Neurosci Lett 1982; 32: 217-21. (Pubitemid 13214144)
85. Koh S, Nelson MD Jr, Kovanlikaya A, Chen LS. Anterior lumbosacral radiculopathy after intrathecal methotrexate treatment. Pediatr Neurol 1999; 21: 576-8. (Pubitemid 29366829)
86. Moore BE, Somers NP, Smith TW. Methotrexate-related nonnecrotizing multifocal axonopathy detected by beta-amyloid precursor protein immunohistochemistry. Arch Pathol Lab Med 2002; 126: 79-81. (Pubitemid 34087638)
87. Boogerd W, Moffie D, Smets LA. Early blindness and coma during intrathecal chemotherapy for meningeal carcinomatosis. Cancer 1990; 65: 452-7.
88. Harila-Saari AH, Huuskonen UE, Tolonen U, Vainionpää LK, Lanning BM. Motor nervous pathway function is impaired after treatment of childhood acute lymphoblastic leukemia: a study with moor evoked potentials. Med Pediatr Oncol 2001; 36: 345-51. (Pubitemid 32198509)
89. Ionasescu VV. Charcot-Marie-Tooth neuropathies: from clinical description to molecular genetics. Muscle Nerve 1995; 18: 267-75.
90. Shibutani M, Okeda R, Hori A, Schipper H. Methotrexate-related multifocal axonopathy. Report of an autopsy case. Acta Neuropathol 1989; 79: 333-5. (Pubitemid 20017609)
91. Weiss S, Kahn Y. Intrathecal methotrexate causing paraplegia in a middle-aged woman. Acta Haematol 1978; 60: 59-61. (Pubitemid 8357129)
92. Kornblau SM, Cortes-Franco J, Estey E. Neurotoxicity associated with fludarabine and cytosine arabinoside chemotherapy for acute leukemia and myelodysplasia. Leukemia 1993; 7: 378-83. (Pubitemid 23093095)
93. Russell JA, Powles RL. Letter: neuropathy due to cytosine arabinoside. Br Med J 1974; 4: 652-3.
94. Cheson BD, Vena DA, Foss FM, Sorensen JM. Neurotoxicity of purine analogs: a review. J Clin Oncol 1994; 12: 2216-28. (Pubitemid 24356042)
95. Dormann AJ, Grünewald T, Wigginghaus B, Huchzermeyer H. Gemcitabine-associated autonomic neuropathy. Lancet 1998; 351: 644. (Pubitemid 28098450)
96. Colomer R, Llombart-Cussac A, Lluch A, et al. Biweekly paclitaxel plus gemcitabine in advanced breast cancer: phase II trial and predictive value of HER2 extracellular domain. Ann Oncol 2004; 15: 201-6. (Pubitemid 38262615)
97. Allegra CJ, Grem JL. Antimetabolites. In: Cancer Principles and Practice in Oncology. 5th ed. De Vita V, Hellman S, Rosenberg SA (eds.). Lippincott-Raven, Philadelphia 1997; 432-52.
98. Moertel CG, Fleming TR, Macdonald JS, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990; 322: 352-8. (Pubitemid 20042739)
99. Stein ME, Drumea K, Yarnitsky D, Benny A, Tzuk-Shina T. A rare event of 5-fluorouracil-associated peripheral neuropathy: a report of two patients. Am J Clin Oncol 1998; 21: 248-9. (Pubitemid 28280134)
100. Saif MW, Wilson RH, Harold N, Keith B, Dougherty DS, Grem JL. Peripheral neuropathy associated with weekly oral 5-fluorouracil, leucovorin and eniluracil. Anticancer Drugs 2001; 12: 525-31. (Pubitemid 32692597)
101. Hamilton S. Hand-foot syndrome. 2005; http://www.chemocare. com/managing/handfoot-syndrome.asp
102. Nagore E, Insa A, Sanmartín O. Antineoplastic therapyinduced palmar plantar erythrodysesthesia ("hand-foot") syndrome. Incidence, recognition and management. Am J Clin Dermatol 2000; 1: 225-34.
103. Russell JW, Gill JS, Sorenson EJ, Schultz DA, Windebank AJ. Suramin-induced neuropathy in an animal model. J Neurol Sci 2001; 192: 71-80. (Pubitemid 32999025)
104. Chaudhry V, Eisenberger MA, Sinibaldi VJ, Sheikh K, Griffin JW, Cornblath DR. A prospective study of suramin-induced peripheral neuropathy. Brain 1996; 119: 2039-52. (Pubitemid 27032634)
105. Hussein MA. Lenalidomide: patient management strategies. Semin Hematol 2005; 42: 22-5.
106. Hansen RA, Gartlehner G, Powell GE, Sandler RS. Serious adverse events with infliximab: analysis of spontaneously reported adverse events. Clin Gastroenterol Hepatol 2007; 5: 729-35.
107. Robertson MJ, Kahl BS, Vose JM, et al. Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol 2007; 25: 1741-6. (Pubitemid 46797955)